Acamprosate Efficacy in Alcohol‐Dependent Patients: Summary of Results from Three Pivotal Trials
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In 2004, the United States Food and Drug Administration (FDA) approved acamprosate for use in conjunction with psychosocial support in the maintenance of abstinence in alcohol‐dependent patients who are abstinent at treatment initiation. That approval was based primarily on a re‐analysis of three European double‐blind, placebo‐controlled trials in which complete abstinence was the primary outcome measure. The current report presents data from the re‐analysis of the pivotal trials, which were 13‐, 48‐, and 52‐week studies. A total of 998 DSM‐III‐R alcohol‐dependent patients were included in the studies, with the majority abstinent at randomization. Using a more stringent definition of abstinence, re‐analysis of the rate of complete abstinence, percent days abstinent, and the time to first drink confirmed the original findings for the efficacy of acamprosate in the treatment of alcohol dependence. Rate of complete abstinence was significantly higher with acamprosate than placebo (p < .05); both percent days abstinent and time to first drink were also significantly greater among acamprosate‐treated than placebo‐treated patients (p < .01). These findings support the use of acamprosate in the treatment of alcohol dependence and illustrate some of the issues that can arise in the FDA process for approval of medications to treat the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444
Drug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255
Friedmann, P. D., McCullough, D., Chin, M. H., & Saitz, R. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.03379.x · Cited by 232
Neuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201
Understanding US addiction physicians' low rate of naltrexone prescription
Mark, T. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00134-0 · Cited by 120
Cited by
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Pharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Metadata
- Authors
- Kranzler, H. R., & Gage, A.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2008-01-02
- Volume
- 17
- Issue
- 1
- Pages
- 70-76
- ISSN
- 1055-0496 (ISSN-L)
- 1521-0391
- OpenAlex
- W2101628508
- Cited by
- 212
- References
- 6
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acamprosate Efficacy in Alcohol‐Dependent Patients: Summary of Results from Three Pivotal Trials. https://app.cochat.ai/papers/10.1080/10550490701756120
- The paper
- Kranzler, H. R., & Gage, A. (2008). Acamprosate Efficacy in Alcohol‐Dependent Patients: Summary of Results from Three Pivotal Trials. The American Journal on Addictions. https://doi.org/10.1080/10550490701756120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.